Generic Kengreal Availability
Last updated on Aug 6, 2025.
Kengreal is a brand name of cangrelor, approved by the FDA in the following formulation(s):
KENGREAL (cangrelor - powder;intravenous)
-
Manufacturer: CHIESI
Approval date: June 22, 2015
Strength(s): 50MG/VIAL [RLD]
Is there a generic version of Kengreal available?
No. There is currently no therapeutically equivalent version of Kengreal available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Kengreal. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Patent 10,039,780
Issued: August 7, 2018
Inventor(s): Dutta Panna & Rafai Far Adel & Ding Min & Motheram Rajeshwar
Assignee(s): Chiesi Farmaceutici S.p.A.The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
Patent expiration dates:
- July 10, 2035✓
- July 10, 2035
-
Methods of treating, reducing the incidence of, and/or preventing ischemic events
Patent 8,680,052
Issued: March 25, 2014
Inventor(s): Arculus-Meanwell Clive Arthur & Skerjanec Simona & Prats Jayne & Schneider David J.
Assignee(s): The Medicines CompanyMethods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Yinhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.
Patent expiration dates:
- March 9, 2033✓
- March 9, 2033
-
Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Patent 9,295,687
Issued: March 29, 2016
Inventor(s): Dutta Panna & Rafai Far Adel & Ding Min & Motheram Rajeshwar
Assignee(s): THE MEDICINES COMPANYThe present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
Patent expiration dates:
- July 10, 2035✓
- July 10, 2035
-
Methods of treating, reducing the incidence of, and/or preventing ischemic events
Patent 9,427,448
Issued: August 30, 2016
Inventor(s): Arculus-Meanwell Clive Arthur & Skerjanec Simona & Prats Jayne
Assignee(s): The Medicines CompanyMethods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Yinhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.
Patent expiration dates:
- November 10, 2030✓
- November 10, 2030
-
Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Patent 9,439,921
Issued: September 13, 2016
Inventor(s): Dutta Panna & Rafai Far Adel & Ding Min & Motheram Rajeshwar
Assignee(s): THE MEDICINES COMPANYThe present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
Patent expiration dates:
- July 10, 2035✓
- July 10, 2035
-
Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Patent 9,700,575
Issued: July 11, 2017
Inventor(s): Dutta Panna & Rafai Far Adel & Ding Min & Motheram Rajeshwar
Assignee(s): Chiesi Farmaceutici, S.P.A.The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
Patent expiration dates:
- July 10, 2035✓
- July 10, 2035
-
Methods of treating or preventing stent thrombosis
Patent 9,925,265
Issued: March 27, 2018
Inventor(s): Arculus-Meanwell Clive Arthur & Skerjanec Simona
Assignee(s): Chiesi Farmaceutici S.p.A.The present invention is directed to the following: methods of treating or preventing stent thrombosis using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; methods of reducing mortality in a subject undergoing stent implantation using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; medicaments comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation; pharmaceutical compositions comprising cangrelor and bivalirudin; and methods of preparing a medicament comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation.
Patent expiration dates:
- May 13, 2029✓
- May 13, 2029
More about Kengreal (cangrelor)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: platelet aggregation inhibitors
Patient resources
Professional resources
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.